Clinical Trials
12 trialsNCT04633252 2026-05-27
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06520345 2026-05-27
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT06925737 2026-05-22
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07213674 2026-05-22
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
NCT07316686 2026-05-18
Lutécio
Instituto do Cancer do Estado de São Paulo
Phase 1 Not yet recruiting
NCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT07590934 2026-05-15
PROSPECTOR
AstraZeneca
Phase 1/2 Not yet recruiting
NCT03574571 2026-05-14
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT06931340 2026-05-08
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06764485 2026-05-06
rechARge
Celgene
Phase 3 Recruiting
NCT05005728 2026-05-05
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT06551324 2026-05-05
MEVPRO-1
Pfizer
Phase 3 Active not recruiting